Targeting a Hallmark of Cancer: Simultaneous Inflammation and Tumor Control for Palliative Care in Metastatic Cancer

  • J. Pfirstinger
  • A. Reichle
  • J. Grassinger


Clinical attenuation of the inflammation-related symptom complex, comprising cachexia, anorexia, fatigue, depression, neuropathic pain, anxiety, cognitive impairment, sleep disorder and delirium, is of extreme importance to improve palliative care in metastatic cancer. Laboratory data provide strong evidence that pro-inflammatory processes are related to multifold clinical disease traits of metastatic cancer and that pro-inflammatory processes are even drivers of tumor progression; however, approaches for attenuating pro-inflammatory processes with single-track or combined single-track therapies repetitively show—as reviewed here—controversial data about the benefit of anti-inflammatory therapies. What are the reasons for the conflicting data? Recently published clinical data indicate that inflammation control in different metastatic tumor types requires differential therapeutic access, because pro-inflammatory processes are multifacetedly rationalized. Beyond the control of inflammation-related clinical symptoms (improved ECOG status) inflammation control is associated with attenuation of tumor growth. Tumor-specific rationalizations provide highly specific targets: Inflammation—as a ubiquitous tumor-associated normative notion—may be constituted in multiple ways, supported by quite different cell types of the tumor compartment. Dependent on the physical constitution of tumor-associated rationalization processes the interfaces to other rationalization processes, e.g., immune response or angiogenesis become displaced and form an obstacle for single-track approaches. Combined modularized, primarily multi-track therapies account for such displacements.


Rest Energy Expenditure Advanced Cancer Patient Glasgow Prognostic Score Palliative Home Care Inflammation Control 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Gupta SC, Kim JH, Kannappan R, Reuter S, Dougherty PM, Aggarwal BB (2011) Role of nuclear factor κB-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents. Exp Biol Med (Maywood) 236(6):658–671CrossRefGoogle Scholar
  2. 2.
    Laviano A, Meguid MM, Rossi-Fanelli F (2003) Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies. Lancet Oncol 4:686–694PubMedCrossRefGoogle Scholar
  3. 3.
    Kurzrock R (2001) Cytokine deregulation in cancer. Biomed Pharmacother 55:543–547PubMedCrossRefGoogle Scholar
  4. 4.
    Kurzrock R (2001) The role of cytokines in cancer-related fatigue. Cancer 92:1684–1688PubMedCrossRefGoogle Scholar
  5. 5.
    Ramamoorthy S, Donohue M, Buck M (2009) Decreased Jun-D and myogenin expression in muscle wasting of human cachexia. Am J Physiol Endocrinol Metab 297:E392–E401.Google Scholar
  6. 6.
    Fortunati N, Manti R, Birocco N, Pugliese M, Brignardello E, Ciuffreda L, Catalano MG, Aragno M, Boccuzzi G (2007) Pro-inflammatory cytokines and oxidative stress/antioxidant parameters characterize the bio-humoral profile of early cachexia in lung cancer patients. Oncol Rep 18:1521–1527PubMedGoogle Scholar
  7. 7.
    Martignoni ME, Kunze P, Hildebrandt W, Kunzli B, Berberat P, Giese T, Kloters O, Hammer J, Buchler MW, Giese NA, Friess H (2005) Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexia. Clin Cancer Res 11:5802–5808PubMedCrossRefGoogle Scholar
  8. 8.
    Inagaki M, Isono M, Okuyama T, Sugawara Y, Akechi T, Akizuki N, Fujimori M, Mizuno M, Shima Y, Kinoshita H, Uchitomi Y (2008) Plasma interleukin-6 and fatigue in terminally ill cancer patients. J Pain Symptom Manage 35:153–161PubMedCrossRefGoogle Scholar
  9. 9.
    Rich T, Innominato PF, Boerner J, Mormont MC, Iacobelli S, Baron B, Jasmin C, Levi F (2005) Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res 11:1757–1764PubMedCrossRefGoogle Scholar
  10. 10.
    Collado-Hidalgo A, Bower JE, Ganz PA, Cole SW, Irwin MR (2006) Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res 12:2759–2766PubMedCrossRefGoogle Scholar
  11. 11.
    Schubert C, Hong S, Natarajan L, Mills PJ, Dimsdale JE (2007) The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav Immun 21:413–427PubMedCrossRefGoogle Scholar
  12. 12.
    Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, Nakano N, Ikeda Y, Sasaki T, Nishioka K, Hara M, Taguchi H, Kimura Y, Kato Y, Asaoku H, Kumagai S, Kodama F, Nakahara H, Hagihara K, Yoshizaki K, Kishimoto T (2005) Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106:2627–2632PubMedCrossRefGoogle Scholar
  13. 13.
    Wang XS, Shi Q, Williams LA, Mao L, Cleeland CS, Komaki RR, Mobley GM, Liao Z. Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav Immun 24:968–974Google Scholar
  14. 14.
    Jehn CF, Kuehnhardt D, Bartholomae A, Pfeiffer S, Krebs M, Regierer AC, Schmid P, Possinger K, Flath BC (2006) Biomarkers of depression in cancer patients. Cancer 107:2723–2729PubMedCrossRefGoogle Scholar
  15. 15.
    Lutgendorf SK, Weinrib AZ, Penedo F, Russell D, DeGeest K, Costanzo ES, Henderson PJ, Sephton SE, Rohleder N, Lucci JA III, Cole S, Sood AK, Lubaroff DM (2008) Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J Clin Oncol 26:4820–4827PubMedCrossRefGoogle Scholar
  16. 16.
    El-Gohary GM, Azzam HM, Ahmed OI, El-Shokry MH (2008) Pro-inflammatory cytokines and depression in patients with acute leukemia. Egypt J Immunol 15:13–24PubMedGoogle Scholar
  17. 17.
    Musselman DL, Miller AH, Porter MR, Manatunga A, Gao F, Penna S, Pearce BD, Landry J, Glover S, McDaniel JS, Nemeroff CB (2001) Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry 158:1252–1257PubMedCrossRefGoogle Scholar
  18. 18.
    Capuron L, Ravaud A, Dantzer R (2000) Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy. J Clin Oncol 18:2143–2151PubMedGoogle Scholar
  19. 19.
    Meyers CA, Albitar M, Estey E (2005) Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 104:788–93PubMedCrossRefGoogle Scholar
  20. 20.
    Guess J, Burch JB, Ogoussan K, Armstead CA, Zhang H, Wagner S, Hebert JR, Wood P, Youngstedt SD, Hofseth LJ, Singh UP, Xie D, Hrushesky WJ (2009) Circadian disruption, Per3, and human cytokine secretion. Integr Cancer Ther 8:329–336PubMedCrossRefGoogle Scholar
  21. 21.
    Costelli P, Carbo N, Tessitore L, Bagby GJ, Lopez-Soriano FJ, Argiles JM, Baccino FM (1993) Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model. J Clin Invest 92:2783–2789PubMedCrossRefGoogle Scholar
  22. 22.
    Llovera M, Garcia-Martinez C, Lopez-Soriano J, Carbo N, Agell N, Lopez-Soriano FJ, Argiles JM (1998) Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice. Mol Cell Endocrinol 142:183–189PubMedCrossRefGoogle Scholar
  23. 23.
    Chen SZ, Qiu ZG (2011) Combined treatment with growth hormone, insulin and indomethacin alleviates cancer cachexia in a mouse model. J Endocrinol 208:131–136PubMedCrossRefGoogle Scholar
  24. 24.
    Cannon TY, Guttridge D, Dahlman J, George JR, Lai V, Shores C, Buzkova P, Couch ME (2007) The effect of altered Toll-like receptor 4 signaling on cancer cachexia. Arch Otolaryngol Head Neck Surg 133:1263–1269PubMedCrossRefGoogle Scholar
  25. 25.
    Opara EI, Laviano A, Meguid MM, Yang ZJ (1995) Correlation between food intake and CSF IL-1 alpha in anorectic tumor bearing rats. Neuroreport 6:750–752PubMedCrossRefGoogle Scholar
  26. 26.
    Laviano A, Gleason JR, Meguid MM, Yang ZJ, Cangiano C, Rossi Fanelli F (2000) Effects of intra-VMN mianserin and IL-1ra on meal number in anorectic tumor-bearing rats. J Invest Med 48:40–48Google Scholar
  27. 27.
    Plata-Salaman CR, Ilyin SE, Gayle D (1998) Brain cytokine mRNAs in anorectic rats bearing prostate adenocarcinoma tumor cells. Am J Physiol 275:R566–573Google Scholar
  28. 28.
    Keller C, Keller P, Giralt M, Hidalgo J, Pedersen BK (2004) Exercise normalises overexpression of TNF-alpha in knockout mice. Biochem Biophys Res Commun 321:179–182PubMedCrossRefGoogle Scholar
  29. 29.
    Wood LJ, Nail LM, Winters KA (2009) Does muscle-derived interleukin-6 mediate some of the beneficial effects of exercise on cancer treatment-related fatigue? Oncol Nurs Forum 36:519–524PubMedCrossRefGoogle Scholar
  30. 30.
    Liu S, Yang J, Wang L, Jiang M, Qiu Q, Ma Z, Liu L, Li C, Ren C, Zhou J, Li W (2010) Tibia tumor-induced cancer pain involves spinal p38 mitogen-activated protein kinase activation via TLR4-dependent mechanisms. Brain Res 1346:213–223PubMedCrossRefGoogle Scholar
  31. 31.
    Zhang RX, Liu B, Li A, Wang L, Ren K, Qiao JT, Berman BM, Lao L (2008) Interleukin 1beta facilitates bone cancer pain in rats by enhancing NMDA receptor NR-1 subunit phosphorylation. Neuroscience 154:1533–1538PubMedCrossRefGoogle Scholar
  32. 32.
    Shih A, Jackson KC 2nd (2007) Role of corticosteroids in palliative care. J Pain Palliat Care Pharmacother 21(4):69–76PubMedCrossRefGoogle Scholar
  33. 33.
    Bruera E, Roca E, Cedaro L, Carraro S, Chacon R (1985) Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 69(7–8):751–754PubMedGoogle Scholar
  34. 34.
    Mercadante S, Fulfaro F, Casuccio A (2001) The use of corticosteroids in home palliative care. Support Care Cancer 9(5):386–389PubMedCrossRefGoogle Scholar
  35. 35.
    Bruera E, Moyano JR, Sala R, Rico MA, Bosnjak S, Bertolino M, Willey J, Strasser F, Palmer JL (2004) Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: a randomized controlled trial. J Pain Symptom Manage 28(4):381–388PubMedCrossRefGoogle Scholar
  36. 36.
    Mercadante SL, Berchovich M, Casuccio A, Fulfaro F, Mangione S (2007) A prospective randomized study of corticosteroids as adjuvant drugs to opioids in advanced cancer patients. Am J Hosp Palliat Care 24(1):13–19PubMedCrossRefGoogle Scholar
  37. 37.
    Pezner RD, Lipsett JA (1982) Peptic ulcer disease and other complications in patients receiving dexamethasone palliation for brain metastasis. West J Med 137(5):375–378PubMedGoogle Scholar
  38. 38.
    Sturdza A, Millar BA, Bana N, Laperriere N, Pond G, Wong RK, Bezjak A (2008) The use and toxicity of steroids in the management of patients with brain metastases. Support Care Cancer 16(9):1041–1048PubMedCrossRefGoogle Scholar
  39. 39.
    Uña Cidón E (2011) Steroids, cancer and vertebral fractures: a dreaded combination. J Oncol Pharm Pract 17(3):279–281PubMedCrossRefGoogle Scholar
  40. 40.
    Lundström S, Fürst CJ, Friedrichsen M, Strang P (2009) The existential impact of starting corticosteroid treatment as symptom control in advanced metastatic cancer. Palliat Med 23(2):165–170PubMedCrossRefGoogle Scholar
  41. 41.
    Bruera E (1992) Clinical management of anorexia and cachexia in patients with advanced cancer. Oncology 49(Suppl 2):35–42PubMedCrossRefGoogle Scholar
  42. 42.
    Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, Krook JE, Wilwerding MB, Rowland KM Jr, Camoriano JK, Novotny PJ, Christensen BJ (1999) Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 17(10):3299–3306PubMedGoogle Scholar
  43. 43.
    Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, Pundaleeka S, Kardinal CG, Fitch TR, Krook JE, Novotny PJ, Christensen B (2002) Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 20(2):567–573PubMedCrossRefGoogle Scholar
  44. 44.
    Jatoi A, Yamashita J, Sloan JA, Novotny PJ, Windschitl HE, Loprinzi CL (2002) Does megestrol acetate down-regulate interleukin-6 in patients with cancer-associated anorexia and weight loss? A North Central Cancer Treatment Group investigation. Support Care Cancer 10(1):71–75PubMedCrossRefGoogle Scholar
  45. 45.
    Dev R, Del Fabbro E, Bruera E (2007) Association between megestrol acetate treatment and symptomatic adrenal insufficiency with hypogonadism in male patients with cancer. Cancer 110(6):1173–1177PubMedCrossRefGoogle Scholar
  46. 46.
    Del Fabbro E, Hui D, Nooruddin ZI, Dalal S, Dev R, Freer G, Roberts L, Palmer JL, Bruera E (2010) Associations among hypogonadism, C-reactive protein, symptom burden, and survival in male cancer patients with cachexia: a preliminary report. J Pain Symptom Manage 39(6):1016–1024PubMedCrossRefGoogle Scholar
  47. 47.
    Shiu SY, Leung WY, Tam CW, Liu VW, Yao KM (2012) Melatonin MT(1) receptor-induced transcriptional up-regulation of p27(Kip1) in prostate cancer antiproliferation is mediated via inhibition of constitutively active nuclear factor kappa B (NF-κB): potential implications on prostate cancer chemoprevention and therapy. J Pineal Res (Epub ahead of print)Google Scholar
  48. 48.
    Shi D, Xiao X, Wang J, Liu L, Chen W, Fu L, Xie F, Huang W, Deng W (2012) Melatonin suppresses proinflammatory mediators in lipopolysaccharide-stimulated CRL1999 cells via targeting MAPK, NF-κB, c/EBPβ, and p300 signaling. J Pineal Res 53(2):154–165PubMedCrossRefGoogle Scholar
  49. 49.
    Wang J, Xiao X, Zhang Y, Shi D, Chen W, Fu L, Liu L, Xie F, Kang T, Huang W, Deng W (2012) Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells. J Pineal Res 53(1):77–90PubMedCrossRefGoogle Scholar
  50. 50.
    Seely D, Wu P, Fritz H, Kennedy DA, Tsui T, Seely AJ, Mills E (2012) Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials. Integr Cancer Ther 11(4):293–303PubMedCrossRefGoogle Scholar
  51. 51.
    Hansen MV, Madsen MT, Hageman I, Rasmussen LS, Bokmand S, Rosenberg J, Gögenur I (2012) The effect of MELatOnin on depression, anxietY, cognitive function and sleep disturbances in patients with breast cancer. The MELODY trial: protocol for a randomised, placebo-controlled, double-blinded trial. BMJ Open 2(1):e000647PubMedCrossRefGoogle Scholar
  52. 52.
    Lundholm K, Gelin J, Hyltander A, Lönnroth C, Sandström R, Svaninger G, Körner U, Gülich M, Kärrefors I, Norli B et al (1994) Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 54(21):5602–5606PubMedGoogle Scholar
  53. 53.
    Fenwick SW, Toogood GJ, Lodge JP, Hull MA (2003) The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases. Gastroenterology 125(3):716–729PubMedCrossRefGoogle Scholar
  54. 54.
    Lönnroth C, Andersson M, Arvidsson A, Nordgren S, Brevinge H, Lagerstedt K, Lundholm K (2008) Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer. Cancer Immun 8:5PubMedGoogle Scholar
  55. 55.
    Lundholm K, Daneryd P, Körner U, Hyltander A, Bosaeus I (2004) Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia. Int J Oncol 24(3):505–512PubMedGoogle Scholar
  56. 56.
    Mantovani G, Macciò A , Madeddu C, Serpe R, Antoni G, Massa E, Dessì M, Panzone F (2010) Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. J Mol Med (Berl) 88(1):85–92Google Scholar
  57. 57.
    Reid J, Hughes CM, Murray LJ, Parsons C, Cantwell MM (2012) Non-steroidal anti-inflammatory drugs for the treatment of cancer cachexia: a systematic review. Palliat Med [Epub ahead of print]Google Scholar
  58. 58.
    Mantovani G, Madeddu C (2008) Cyclooxygenase-2 inhibitors and antioxidants in the treatment of cachexia. Curr Opin Support Palliat Care 2(4):275–281PubMedCrossRefGoogle Scholar
  59. 59.
    Bayliss TJ, Smith JT, Schuster M, Dragnev KH, Rigas JR (2011) A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin Biol Ther 11(12):1663–1668CrossRefGoogle Scholar
  60. 60.
    Fizazi K, De Bono JS, Flechon A, Heidenreich A, Voog E, Davis NB, Qi M, Bandekar R, Vermeulen JT, Cornfeld M, Hudes GR (2012) Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. Eur J Cancer 48(1):85–93PubMedCrossRefGoogle Scholar
  61. 61.
    Hudes G, Tagawa ST, Whang YE, Qi M, Qin X, Puchalski TA, Reddy M, Cornfeld M, Eisenberger M (2012) A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer. Invest New Drugs [Epub ahead of print]Google Scholar
  62. 62.
    Tookman AJ, Jones CL, DeWitte M, Lodge PJ (2008) Fatigue in patients with advanced cancer: a pilot study of an intervention with infliximab. Support Care Cancer 16(10):1131–1140PubMedCrossRefGoogle Scholar
  63. 63.
    Jatoi A, Dakhil SR, Nguyen PL, Sloan JA, Kugler JW, Rowland KM Jr, Soori GS, Wender DB, Fitch TR, Novotny PJ, Loprinzi CL (2007) A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group. Cancer 110(6):1396–1403PubMedCrossRefGoogle Scholar
  64. 64.
    Madhusudan S, Foster M, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C, Hoare S, Balkwill F, Talbot DC, Ganesan TS, Harris AL (2004) A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin Cancer Res 10(19):6528–6534PubMedCrossRefGoogle Scholar
  65. 65.
    Madhusudan S, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C, Hoare S, Balkwill F, Ganesan TS (2005) Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. J Clin Oncol 23(25):5950–5959PubMedCrossRefGoogle Scholar
  66. 66.
    Majumdar S, Lamothe B, Aggarwal BB (2002) Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester. J Immunol 168(6):2644–2651PubMedGoogle Scholar
  67. 67.
    Anderson KC (2005) Lenalidomide and thalidomide: mechanisms of action–similarities and differences. Semin Hematol 42(4 Suppl 4):S3–S8Google Scholar
  68. 68.
    Bruera E, Neumann CM, Pituskin E, Calder K, Ball G, Hanson J (1999) Thalidomide in patients with cachexia due to terminal cancer: preliminary report. Ann Oncol 10(7):857–859PubMedCrossRefGoogle Scholar
  69. 69.
    Yennurajalingam S, Willey JS, Palmer JL, Allo J, Del Fabbro E, Cohen EN, Tin S, Reuben JM, Bruera E (2012) The role of thalidomide and placebo for the treatment of cancer-related anorexia-cachexia symptoms: results of a double-blind placebo-controlled randomized study. J Palliat Med 15(10):1059–1064PubMedCrossRefGoogle Scholar
  70. 70.
    Cerchietti LC, Navigante AH, Castro MA (2007) Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer. Nutr Cancer 59(1):14–20PubMedCrossRefGoogle Scholar
  71. 71.
    Jatoi A, Rowland K, Loprinzi CL, Sloan JA, Dakhil SR, MacDonald N, Gagnon B, Novotny PJ, Mailliard JA, Bushey TI, Nair S, Christensen B, North Central Cancer Treatment G (2004) An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol 22(12):2469–2476PubMedCrossRefGoogle Scholar
  72. 72.
    Kraft M, Kraft K, Gärtner S, Mayerle J, Simon P, Weber E, Schütte K, Stieler J, Koula-Jenik H, Holzhauer P, Gröber U, Engel G, Müller C, Feng YS, Aghdassi A, Nitsche C, Malfertheiner P, Patrzyk M, Kohlmann T, Lerch MM (2012) L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)—a randomized multicentre trial. Nutr J 11:52PubMedCrossRefGoogle Scholar
  73. 73.
    Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W, Ko YD, Schnelle M, Reif M, Cerny T (2006) Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 24(21):3394–3400PubMedCrossRefGoogle Scholar
  74. 74.
    Mantovani G, Macciò A , Madeddu C, Gramignano G, Lusso MR, Serpe R, Massa E, Astara G, Deiana L (2006) A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress. Cancer Epidemiol Biomarkers Prev 15(5):1030–1034Google Scholar
  75. 75.
    Mantovani G, Macciò A , Madeddu C, Serpe R, Massa E, Dessì M, Panzone F, Contu P (2010) Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist 15(2):200–211Google Scholar
  76. 76.
    Mantovani G (2010) Randomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia. Eur Rev Med Pharmacol Sci 14(4):292–301PubMedGoogle Scholar
  77. 77.
    Macciò A, Madeddu C, Gramignano G, Mulas C, Floris C, Sanna E, Cau MC, Panzone F, Mantovani G (2012) A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life. Gynecol Oncol 124(3):417–425Google Scholar
  78. 78.
    Mock V, Atkinson A, Barsevick A, Cella D, Cimprich B, Cleeland C, Donnelly J, Eisenberger MA, Escalante C, Hinds P, Jacobsen PB, Kaldor P, Knight SJ, Peterman A, Piper BF, Rugo H, Sabbatini P, Stahl C; National Comprehensive Cancer Network (2000) NCCN Practice Guidelines for Cancer-Related Fatigue. Oncology (Williston Park) 14(11A):151–161Google Scholar
  79. 79.
    Radbruch L, Elsner F, Trottenberg P, Strasser F, Fearon K (2010) Clinical practice guidelines on cancer cachexia in advanced cancer patients. Aachen, Department of Palliative Medicine/European Palliative Care Research CollaborativeGoogle Scholar
  80. 80.
    Dy SM, Lorenz KA, Naeim A, Sanati H, Walling A, Asch SM (2008) Evidence-based recommendations for cancer fatigue, anorexia, depression, and dyspnea. J Clin Oncol 26(23):3886–3895PubMedCrossRefGoogle Scholar
  81. 81.
    Reichle A, Hildebrandt GC (2010) The comparative uncovering of tumor systems biology by modularly targeting tumor therapy. In: Reichle A (ed) From molecular to modular tumor therapy: the tumor microenvironment, vol 3, part 4. Springer, pp 287–303Google Scholar
  82. 82.
    Reichle A, Vogt T (2008) Systems biology: a therapeutic target for tumor therapy. Cancer Microenviron 1(1):159–170PubMedCrossRefGoogle Scholar
  83. 83.
    Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG, Coward JI, Schioppa T, Robinson SC, Gallagher WM, Galletta L, Australian Ovarian Cancer Study Group, Salako MA, Smyth JF, Hagemann T, Brennan DJ, Bowtell DD, Balkwill FR (2012) A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res 72(1):66–75PubMedCrossRefGoogle Scholar
  84. 84.
    Mantovani A, Marchesi F, Porta C, Sica A, Allavena P (2007) Inflammation and cancer: breast cancer as a prototype. Breast 16(Suppl 2):S27–S33PubMedCrossRefGoogle Scholar
  85. 85.
    Porta C, Larghi P, Rimoldi M, Totaro MG, Allavena P, Mantovani A, Sica A (2009) Cellular and molecular pathways linking inflammation and cancer. Immunobiology 214(9–10):761–777PubMedCrossRefGoogle Scholar
  86. 86.
    Solinas G, Germano G, Mantovani A, Allavena P (2009) Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 86(5):1065–1073PubMedCrossRefGoogle Scholar
  87. 87.
    Pahler JC, Tazzyman S, Erez N et al (2008) Plasticity in tumor promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. Neoplasia 10:329–340PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  1. 1.Department of Hematology and OncologyUniversity Hospital RegensburgRegensburgGermany

Personalised recommendations